Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
复制标题
DOI：
10.2147/dddt.s110131
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Garcia JM
中科院分区：
文献类型：
--
作者：
Graf SA;Garcia JM
癌症厌食恶病质综合征(CACS)是晚期癌症中常见的一种复杂且大部分无法治疗的副肿瘤并发症。它与对生活质量和生存的深远有害影响有关。自十多年前被发现以来，盐酸阿莫瑞林(Anamorelin)，一种生长激素促分泌剂Ghrelin的模拟物，在用于晚期癌症患者时，在改善CACs的成分方面显示出相当大的希望，包括瘦体重减轻和厌食症的逆转。本文综述了阿那莫瑞林的研究进展及其在临床研究中的安全性和有效性。此外，还讨论了阿那莫瑞林在治疗CACs方面的潜在作用。
Cancer anorexia–cachexia syndrome (CACS) is a complex and largely untreatable paraneoplastic complication common in advanced cancer. It is associated with profoundly deleterious effects on quality of life and survival. Since its discovery over a decade ago, anamorelin hydrochloride (anamorelin), a mimetic of the growth hormone secretagogue ghrelin, has shown considerable promise in ameliorating components of CACS when administered to patients with advanced cancer, including loss of lean body mass and reversal of anorexia. This review summarizes the development of anamorelin and its safety and efficacy in clinical investigations. The potential future role of anamorelin in treating CACS is also discussed.